Skip to main content
SpringerLink
Log in

Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis

  • Rhinology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Purpose

Allergic fungal rhinosinusitis (AFRS) is a common disorder with a high prevalence and a very high incidence of recurrence. Management includes surgery and medical treatment in the form of local and/or systemic steroids. However, some cases are resistant to the action of steroids and further treatment is warranted. Being an immune-mediated disorder, targeting IgE seems a logical step. Immunotherapy drugs acting on the IgE (e.g. omalizumab) can modify the clinical course of the disease. This study aimed at evaluating the effect of omalizumab on the clinical course of patients undergoing surgery for AFRS.

Materials and methods

This is a two-arm prospective, randomized, single blind clinical trial among patients with AFRS. Twenty patients were included and randomly divided into two groups: Group A; 10 patients received a single subcutaneous injection of omalizumab (Xolair ‘ Novartis) (150 mg) 2 weeks postoperatively. Group B: 10 patients received local steroids nasal sprays (budesonide or mometasone furoate, 100 μg twice daily for 6 months, starting 2 weeks postoperatively. All patients underwent history, examination, CT scan and IgE level estimation and were submitted to endoscopic sinus surgery. They were evaluated at 4 weeks interval for 6 months.

Results

In both groups there were highly significant differences between pre/post-operative SNOT-20 scores, TNSS scores, total IgE level and Philpott–Javer staging scores. Comparison between the two study groups at 24 weeks showed a highly significant difference (p = 0.001) between post-operative SNOT 20 and TNSS scores in favour of group A. There was no statistically significant difference between the two study groups as regarding postoperative total IgE or Philpott–Javer scores. There were two recurrences in both arms, but no significant side effects.

Discussion

We compared a single post operative injection of omalizumab with twice daily intranasal steroid spray for 6 months. Both treatments were effective, but the omalizumab group showed a more significant clinical and endoscopic response. There were no significant side effects in both arms. This novel approach used a single low dose injection of omalizumab increased the compliance of the patients with minimal complications. Longer follow-up of the patients is ongoing to determine the optimal time for re-injection. The only downside was the higher cost of omalizumab compared to that of local steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khattar VS, Hathiram BT (2009) Allergic fungal rhinosinusitis. Otorhinolaryngol Clin 1:37–44

    Article  Google Scholar 

  2. Ferguson BJ, Barnes L, Bernstein JM et al (2000) Geographic variation in allergic fungal rhinosinusitis. Otolaryngol Clin N Am 33:441–449

    Article  CAS  Google Scholar 

  3. Mostafa BE, El Sharnoubi MMK, El Sersy HA, Mahmoud MSM (2016) Environmental risk factors in patients with noninvasive fungal sinusitis. Scientifica 2016:1–5

    Article  Google Scholar 

  4. Laury AM, Wise SK (2013) Allergic fungal rhinosinusitis. Am J Rhinol Allergy 27:26–27

    Article  Google Scholar 

  5. Loftus PA, Wise SK (2016) Allergic fungal rhinosinusitis: the latest in diagnosis and management. Adv Otorhinolaryngol 79:13–20

    PubMed  Google Scholar 

  6. Gan EC, Thamboo A, Rudmik L et al (2014) Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence-based review and recommendations. Intl Forum of Allergy Rhinol 4(9):702–715

    Article  Google Scholar 

  7. Bachert C, Pawankar R, Zhang L et al (2014) Chronic rhinosinusitis. World Allergy Organ J 7:1

    Article  Google Scholar 

  8. Gan EC, Habib AR, Rajwani A et al (2015) Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma. Am J Otolaryngol Head Neck Med Surg 36:672–677

    Google Scholar 

  9. Galal N, Shawky A, El-Fouly M et al (2016) Level of total and specific fungus IgE in allergic fungal sinusitis: how it affects management and follow-up. Pan Arab J Rhinol 06:45–50

    Article  Google Scholar 

  10. Kuhn FA, Javer AR (2000) Allergic fungal sinusitis: a four-year followup. Am J Rhinol 14:149–156

    Article  CAS  Google Scholar 

  11. Gupta A, Shah N, Kamezwaran M et al (2012) Allergic fungal rhinosinusitis. Clin Rhinol An Int J 5:72–86

    Article  Google Scholar 

  12. Mabry RL, Mabry CS (2000) Allergic fungal sinusitis: the role of immunotherapy. Otolaryngol Clin N Am 33(2):433–440

    Article  CAS  Google Scholar 

  13. Holgate S, Smith N, Massanari M, Jimenez P (2009) Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 64(12):1728–1736

    Article  CAS  Google Scholar 

  14. Evans MO II, Coop CA (2014) Novel treatment of allergic fungal sinusitis using omalizumab. Allergy Rhinol 5:172–174

    Article  Google Scholar 

  15. Suri N, Bhavya BM (2018) Allergic fungal rhinosinusitis: an overview on pathogenesis, early diagnosis and management. Int J Otorhinolaryngol Head Neck Surg 4(3):694–700

    Article  Google Scholar 

  16. Tyler MA, Luong AU (2018) Current understanding of allergic fungal rhinosinusitis. World J Otorhinolaryngol Head Neck Surg 4:179–185

    Article  Google Scholar 

  17. Bent JP III, Kuhn FA (1994) Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 111:580–588

    Article  Google Scholar 

  18. Philpott CM, Clark A, Javer AR (2011) Allergic fungal rhinosinusitis, a new staging system. Rhinology 49:318–323

    Article  CAS  Google Scholar 

  19. Adam SD, Todd EB, Jess CM et al (2016) Development of a clinically relevant endoscopic grading system for chronic rhinosinusitis using canonical correlation analysis. Int Forum Allergy Rhinol 6(5):478–485

    Article  Google Scholar 

  20. Luong A, Marple BF (2004) Allergic fungal rhinosinusitis. Curr Allergy Asthma Rep 4:465–470

    Article  Google Scholar 

  21. Lu-Myers Y, Deal AM, Miller JD et al (2015) Comparison of socioeconomic and demographic factors in patients with chronic rhinosinusitis and allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg 153:137–143

    Article  Google Scholar 

  22. Reda R, Wageh W, Fawaz M et al (2019) Comparison between local steroids and local steroids plus itraconazole effect in prevention of recurrence of allergic fungal sinusitis in hypertensive and/or diabetic patients. EJO 35:25–29

    Google Scholar 

  23. Mullings WP, Al-Salman R, Javer AR (2018) Managing allergic fungal rhinosinusitis. Current otorhinolaryngology reports. Springer Science + Business Media, Berlin

    Google Scholar 

  24. Ferguson B (2004) Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 12:237–242

    Article  Google Scholar 

  25. Penn R, Mikula S (2007) The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 21:428–432

    Article  Google Scholar 

  26. El-Qutob D (2016) Off-label uses of omalizumab. Clinic Rev Allergy Immunol 50(1):84–96

    Article  CAS  Google Scholar 

  27. Lin H, Boesel KM, Griffith DT et al (2004) Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 113(2):297–302

    Article  CAS  Google Scholar 

  28. Gevaert P, Calus L, Van-Zele T et al (2013) Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110–116

    Article  CAS  Google Scholar 

  29. Tajiri T, Matsumoto H, Hiraumi H et al (2013) Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 110(5):387–388

    Article  CAS  Google Scholar 

  30. Roberts G, Xatzipsalti M, Borrego LM et al (2013) Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 68(9):1102–1116

    CAS  PubMed  Google Scholar 

  31. Hong CJ, Tsang AC, Quinn JG et al (2015) Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review. Syst Rev 4:166

    Article  Google Scholar 

  32. Lowe PJ, Tannenbaum S, Gautler A et al (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68(1):61–76

    Article  CAS  Google Scholar 

  33. Vennera MC, Picado C, Mullol J et al (2011) Efficacy of omalizumab in treatment of nasal polyps. Thorax 66:824–825

    Article  Google Scholar 

  34. Saini S, Rosen KE, Hsieh HJ et al (2011) A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128:567–573

    Article  CAS  Google Scholar 

  35. Subramaniyan R, Chopra A (2016) Treatment of chronic spontaneous urticaria with a single dose of omalizumab: a study of four cases. Indian J Dermatol 61(4):467

    Article  Google Scholar 

  36. Simpson RS, Lee JK (2019) Omalizumab as single-dose therapy for vernal keratoconjunctivitis. Lett Ann Allergy Asthma Immunol 122:117–123

    Article  Google Scholar 

  37. Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH (2018) Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 56(1):42–45

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Ain-Shams University, 75 El Nozha Street, Heliopolis-Cairo, 11351, Egypt

    Badr Eldin Mostafa, Michael Fadel, Mohammed Amir Mohammed, Tarek Abdel Hamid Hamdi & Anas Mohammed Askoura

Authors
  1. Badr Eldin Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Fadel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammed Amir Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tarek Abdel Hamid Hamdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anas Mohammed Askoura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Badr Eldin Mostafa.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mostafa, B.E., Fadel, M., Mohammed, M.A. et al. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis. Eur Arch Otorhinolaryngol 277, 121–128 (2020). https://doi.org/10.1007/s00405-019-05650-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-019-05650-y

Keywords

Search

Navigation